Flavonoids from Hypericum perforatum Show Antidepressant Activity in the Forced Swimming Test

Abstract

It has been shown recently that a flavonoid fraction (fraction II) obtained from a crude extract of Hypericum perforatum (St. John's wort) was remarkably active in the forced swimming test (FST). Fraction II was further separated using MLCCC to give fractions IIa and IIb. Both fractions proved to be active in the FST at different dosages. Further separation of fraction IIa by preparative HPLC yielded fraction IIa₁ which mainly was composed of hyperoside, isoquercitrin, miquelianin and quercitrin, and fraction IIa₂ which contained small amounts of hyperoside and astilbin, while most compounds were not known. Both fractions were active after acute treatment in the FST. Isolates obtained from these fractions including hyperoside, isoquercitrin, quercitrin, miquelianin, the aglycone quercetin and astilbin, were tested for activity in the FST. Except for quercetin, quercitrin and astilbin all compounds were active. To exclude false positive results in the FST the validity was checked in open field experiments and in the FST after 12 days of daily treatment.

References

• 1 Nahrstedt  A,, Butterweck  V.. Biologically active and other chemical constituents of the herb of Hypericum perforatum. .  Pharmacopsychiatry. 1997;;  30 (Suppl) 129-134
• 2 Butterweck  V,, Wall  A,, Lieflaender-Wulf  U,, Winterhoff  H,, Nahrstedt  A.. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;;  30 (Suppl) 117-124
• 3 Butterweck  V,, Petereit  F,, Winterhoff  H,, Nahrstedt  A.. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the Forced Swimming Test.  Planta Medica. 1998;;  64 291-294
• 4 Bhattacharya  S K,, Chakrabarti  A,, Chatterjee  S S.. Activity profiles of two hyperforin-containing Hypericum extracts in behavioural models.  Pharmacopsychiatry. 1998;;  31 (Suppl) 22-29
• 5 Chatterjee  S S,, Bhattacharya  S K,, Wonnemann  M,, Singer  A,, Müller  W E.. Hyperforin as a possible antidepressant compound of Hypericum extracts.  Life Sciences. 1998;;  63 499-510
• 6 Porsolt  R D,, Le Pichon  M,, Jalfre  M.. Depression: a new animal model sensitive to antidepressant treatments.  Nature. 1977;;  266 730-732
• 7 Porsolt  R D,, Anton  G,, Blavet  N,, Jalfre  M.. Behavioural despair in rats: A new model sensitive to antidepressant treatments.  European Journal of Pharmacology. 1978,;  47 379-391
• 8 Vogel  G H,, Vogel  W H.. Drug Discovery and Evaluation. Springer, Berlin Heidelberg; 1997;: 206-207
• 9 Sparenberg  B,, Demisch  L,, Hoelzl  J.. Untersuchungen über antidepressive Wirkstoffe von Johanniskraut.  Pharmazeutische Zeitung Wissenschaft. 1993;;  6 (138) 50-54
• 10 Thiede  H M,, Walper  A.. Inhibition of MAO and COMT by Hypericum extracts and hypericin.  Journal of Geriatric Psychiatry and Neurology. 1994;;  7 (Suppl. 1) 54-56
• 11 Baureithel  K H,, Büter  K B,, Engesser  A,, Burkard  W,, Schaffner  W.. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. .  Pharmaceutica Acta Helvetiae. 1997;;  72 153-157
• 12 Simmen  U,, Schweitzer  C,, Burkard  W,, Schaffner  W,, Lundstrom  K.. Hypericum perforatum inhibits the binding of μ and κ opiod receptor expressed with the Semliki Forest virus system.  Pharmaceutica Acta Helvetiae. 1998;;  73 53-56
• 13 Ito  Y,, Conway  W.. Development of countercurrent chromatography.  Analytical Chemistry. 1984;;  56 534-554